Lysophosphatidylcholine acyltransferase 1 altered phospholipid composition and regulated hepatoma progression.
about
Hepatocellular carcinoma: Review of disease and tumor biomarkersLysophosphatidylcholine acyltransferase 1 upregulation and concomitant phospholipid alterations in clear cell renal cell carcinomaImaging mass spectrometry distinguished the cancer and stromal regions of oral squamous cell carcinoma by visualizing phosphatidylcholine (16:0/16:1) and phosphatidylcholine (18:1/20:4).Lysophosphatidylcholine acyltransferase1 overexpression promotes oral squamous cell carcinoma progression via enhanced biosynthesis of platelet-activating factor.Mass Spectrometry-based Lipidomics and Its Application to Biomedical ResearchOverexpression of Lysophosphatidylcholine Acyltransferase 1 and Concomitant Lipid Alterations in Gastric Cancer.Decreased expression of lysophosphatidylcholine (16:0/OH) in high resolution imaging mass spectrometry independently predicts biochemical recurrence after surgical treatment for prostate cancer.MALDI mass spectrometry imaging: A cutting-edge tool for fundamental and clinical histopathology.Phospholipids as cancer biomarkers: Mass spectrometry-based analysis.Accumulation of arachidonic acid-containing phosphatidylinositol at the outer edge of colorectal cancer.In situ biomarker discovery and label-free molecular histopathological diagnosis of lung cancer by ambient mass spectrometry imaging.Matrix-assisted laser desorption/ionization imaging mass spectrometry reveals changes of phospholipid distribution in induced pluripotent stem cell colony differentiation.The hepatic lipidome: a gateway to understanding the pathogenesis of alcohol-induced fatty liverLipidomic Signatures and Associated Transcriptomic Profiles of Clear Cell Renal Cell CarcinomaUnderstanding the connection between platelet-activating factor, a UV-induced lipid mediator of inflammation, immune suppression and skin cancer.Integrated analysis of long noncoding RNA and coding RNA expression in esophageal squamous cell carcinoma.Serum lipid alterations identified in chronic hepatitis B, hepatitis B virus-associated cirrhosis and carcinoma patients.AAV-mediated lysophosphatidylcholine acyltransferase 1 (Lpcat1) gene replacement therapy rescues retinal degeneration in rd11 mice.Proteomic and metabonomic biomarkers for hepatocellular carcinoma: a comprehensive review.Recurrent triple-negative breast cancer (TNBC) tissues contain a higher amount of phosphatidylcholine (32:1) than non-recurrent TNBC tissues.Essential Role of Lysophosphatidylcholine Acyltransferase 3 in the Induction of Macrophage Polarization in PMA-Treated U937 Cells.Reduced levels of N'-methyl-2-pyridone-5-carboxamide and lysophosphatidylcholine 16:0 in the serum of patients with intrahepatic cholangiocarcinoma, and the correlation with recurrence-free survival.Lysophosphatidylcholine acyltransferase 2-mediated lipid droplet production supports colorectal cancer chemoresistance.Comparison of hepatic and serum lipid signatures in hepatocellular carcinoma patients leads to the discovery of diagnostic and prognostic biomarkers.The stearate-to-palmitate ratio modulates endoplasmic reticulum stress and cell apoptosis in non-B non-C hepatoma cells.Analogy between non-alcoholic steatohepatitis (NASH) and hypertension: a stepwise patient-tailored approach for NASH treatment.
P2860
Q26750796-48594C02-B75A-4E84-9200-5AAE930CB521Q33667501-D9EC52B4-F30F-4B3A-87E5-6F566E390A97Q34752225-5337291F-1361-4BB1-9EA2-02B929CA7B0DQ35214355-FE4A2CDC-1286-4137-925F-A57B9FC1024CQ35332947-02A4F295-9240-4509-809C-CF497425E73EQ35573943-55FEFF63-6BB2-4AFB-8B0E-81457A28FF10Q35762498-BB7710F3-EBC2-4E3C-852E-F689D0B6ECC0Q36020378-12EC8D25-41C1-4FA5-92BC-54299C3D1376Q36045221-DAF8385E-2CD0-438F-9F3C-859B50B8D319Q36082169-457757DA-D2D5-49A0-9B9E-265C4916BC40Q36099880-0D21D585-835D-4267-9A21-B3EE26CC51DDQ36183378-02BCD9A6-28F6-4507-9884-B03B9315D6D1Q36590606-9C8C67DC-968A-487C-AEE0-02C95FE8592FQ37054261-1279F245-0E88-4E0D-80BE-EE393D14491DQ37156655-650AC2C8-C7F0-401F-87F5-732444EAE813Q37270399-293FF7D2-14E0-41A7-AC97-7B86BF947676Q37642807-B8EBC5D6-C0F6-42EB-A08C-33512C792548Q37671074-B05BA558-3BEC-46BF-95CA-B1D238A3C97AQ38397273-CFF61FCD-4E8B-45C0-A668-D610B5DD0147Q38638301-AA9F4CCC-B2A1-4912-9E16-34F180263687Q41212304-7ED8E4B3-DEE8-4D12-9F8F-70C0525B85F0Q47559129-9485FDF0-C0C4-4790-9677-5E4F915C2EE9Q49865078-C20D259C-0309-451F-AA0A-5A1218E2E7BBQ50052924-CBA70FCF-456E-4D5C-8791-B781C8DC7611Q50088540-E7A2191A-D017-4928-AD6F-764404974E0CQ55323878-9B29D057-9418-43C0-B4C6-0EFEEC73FCF3
P2860
Lysophosphatidylcholine acyltransferase 1 altered phospholipid composition and regulated hepatoma progression.
description
2013 nî lūn-bûn
@nan
2013 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2013 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
name
Lysophosphatidylcholine acyltr ...... egulated hepatoma progression.
@ast
Lysophosphatidylcholine acyltr ...... egulated hepatoma progression.
@en
Lysophosphatidylcholine acyltr ...... egulated hepatoma progression.
@nl
type
label
Lysophosphatidylcholine acyltr ...... egulated hepatoma progression.
@ast
Lysophosphatidylcholine acyltr ...... egulated hepatoma progression.
@en
Lysophosphatidylcholine acyltr ...... egulated hepatoma progression.
@nl
prefLabel
Lysophosphatidylcholine acyltr ...... egulated hepatoma progression.
@ast
Lysophosphatidylcholine acyltr ...... egulated hepatoma progression.
@en
Lysophosphatidylcholine acyltr ...... egulated hepatoma progression.
@nl
P2093
P1476
Lysophosphatidylcholine acyltr ...... egulated hepatoma progression.
@en
P2093
Atsushi Suzuki
Hiroki Tanaka
Hiroyuki Konno
Kazuhiko Fukumoto
Keisuke Inaba
Koji Ikegami
Makoto Murakami
Mitsutoshi Setou
Naoko Goto-Inoue
Takahiro Hayasaka
P304
P356
10.1016/J.JHEP.2013.02.030
P577
2013-04-06T00:00:00Z